The Business workshop was truly a fantastic experience! The team at ModelZ brought a wealth of knowledge and expertise to the table, and their innovative approach to business strategy was both engaging and thought-provoking. The workshop was a great opportunity for our team to come together and collaborate on creating
This Wednesday (Feb 15th), I will attend the OurCrowd summit in Jerusalem. Happy to meet and discuss with individuals and potential Investors who are interested in NurExone Biologic‘s unique therapy and technology platform to treat damage in the Central Nervous System (#CNS) with the potential to treat Spinal Cord Injuries
Today is the OurCrowd Global Investor Summit, and it is an incredible event. The conference is sold out, with over 10,000 attendees in the heart of Jerusalem, Israel. #investors , #institutionalinvestors , #familyoffices #vc, from all over the world have come to meet Israeli entrepreneurs and companies of the #israelitech eco-system. As a #Canadian financier, I like to speak with Israeli entrepreneurs
NurExone Biologic is developing a revolutionary biological Extracellular Vesicles (EVs)-based technology drug platform to provide functional recovery from damage in the central nervous system (CNS). According to the National Cancer Institute (NCI), exosomes which look like tiny sacs approximately 30 to 150 nm in diameter are formed inside a cell and contain
The current study was designed to assess the impact of ExoPTEN on the motor, reflex, and sensory recovery of rats, following full transection (i.e. complete severing) of the spinal cord. Read More >>>
NurExone has established itself as a unique company by possessing both a product in development, ExoPTEN, and an advanced platform for the production and loading of exosomes. This combination aims to position the company ahead of its competitors in terms of effectiveness and efficiency. Read More >>>
The company is developing treatment for full or partial reversal of paralysis and improving the lives of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequences. NurExone’s technology is being used to develop treatment of various conditions, including spinal cord
The Patent discloses and claims groundbreaking inventions and methods in exosome technology, such as the pharmaceutical compositions comprising extracellular vesicles including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor as well as a method for treating neuronal injury or damage, including intranasal administration. Read More
It has been an outstanding year with significant scientific and business developments! We move forward to a greater achievements and accomplishments! Read More …
